Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/25/2024 | $5.00 | Buy | Canaccord Genuity |
| 5/1/2024 | $10.00 → $8.00 | Outperform | Telsey Advisory Group |
| 7/24/2023 | Outperform → Mkt Perform | Raymond James | |
| 9/9/2022 | $12.00 | Buy | DA Davidson |
| 8/22/2022 | $11.00 | Outperform | Raymond James |
| 8/17/2022 | $11.00 | Buy | Jefferies |
| 7/19/2022 | $13.00 | Outperform | Telsey Advisory Group |
SC 13D/A - Waldencast plc (0001840199) (Subject)
SC 13G - Waldencast plc (0001840199) (Subject)
SC 13G/A - Waldencast plc (0001840199) (Subject)
NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast" or "the Company"), a global multi-brand beauty and wellness platform, today announced the formation of a new Creative Council. The interdisciplinary team of industry disruptors will come together to help Waldencast stay ahead of the curve by ideating on long-term macro and micro-trends in the beauty and wellness industry, and to ensure the Company evolves to meet customer needs now and in the future. The Creative Council will focus on what is next in beauty, wellness, and culture. The goal of the powerhouse group is to provide a pulse on trends and become the dreamers and makers of what these industrie
LONG BEACH, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC ("Obagi"), a leader in skincare innovation and the originator of medical-grade skincare, is thrilled to announce the appointment of Dr. Suzan Obagi as the Company's first-ever Chief Medical Director. Obagi is a subsidiary of Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform and publicly listed company. Dr. Obagi brings a wealth of experience and expertise to her role, further solidifying Obagi's commitment to providing advanced, transformative skincare solutions. Dr. Suzan Obagi is a world-renowned, leading board-certified dermatologist and cosmetic surgeon, recogni
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Waldencast plc (NASDAQ:WALD) investors that a lawsuit was filed on behalf of investors that purchased Waldencast securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. Waldencast revealed on January 31, 2024, that Philippe Gau
4 - Waldencast Acquisition Corp. (0001840199) (Issuer)
3 - Waldencast Acquisition Corp. (0001840199) (Issuer)
3 - Waldencast Acquisition Corp. (0001840199) (Issuer)
$70.2 million of Net Revenue Q3 2024+34.6% Comparable Net Revenue GrowthBoth brands accelerating from Q2 2024+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023 LONDON, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended September 30, 2024 ("Q3 2024") and nine months ended September 30, 2024 ("Nine Months 2024") on Form 6-K to the U.S. Securities and Exchange Commission, which are also available on the Company's investor relations site at http://ir.waldencast.com/. Michel Brouss
LONDON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform provided the details for its Third Quarter Fiscal 2024 conference call and webcast. As previously announced, the Company will issue its Third Quarter Fiscal 2024 results on November 20, 2024 after the close of the U.S. market. Management will host a conference call to discuss its Third Quarter Fiscal 2024 results on November 21, 2024 at 8:30am ET. Investors and analysts interested in participating in the conference call are invited to dial (877) 704-4453 or (201) 389-0920 for international callers. The conference call will be webcast live and include
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, announced today that Hind Sebti, Kelly Brookie and Roberto Thompson have been appointed to its board of Directors (the "Board"), effective September 26, 2024. These executives bring extensive professional experience further enhancing the breadth of talent and expertise possessed by the Board. Ms. Brookie will replace Sarah Brown who has informed the Board of her intention to not renew her mandate ahead of the Company's Annual General Meeting. The Company also announced that its Annual General Meeting is scheduled for October 28, 2024 d
6-K - Waldencast plc (0001840199) (Filer)
6-K - Waldencast plc (0001840199) (Filer)
20-F/A - Waldencast plc (0001840199) (Filer)
Canaccord Genuity initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00
Telsey Advisory Group reiterated coverage of Waldencast plc with a rating of Outperform and set a new price target of $8.00 from $10.00 previously
Raymond James downgraded Waldencast plc from Outperform to Mkt Perform
$70.2 million of Net Revenue Q3 2024+34.6% Comparable Net Revenue GrowthBoth brands accelerating from Q2 2024+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023 LONDON, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended September 30, 2024 ("Q3 2024") and nine months ended September 30, 2024 ("Nine Months 2024") on Form 6-K to the U.S. Securities and Exchange Commission, which are also available on the Company's investor relations site at http://ir.waldencast.com/. Michel Brouss
LONDON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform provided the details for its Third Quarter Fiscal 2024 conference call and webcast. As previously announced, the Company will issue its Third Quarter Fiscal 2024 results on November 20, 2024 after the close of the U.S. market. Management will host a conference call to discuss its Third Quarter Fiscal 2024 results on November 21, 2024 at 8:30am ET. Investors and analysts interested in participating in the conference call are invited to dial (877) 704-4453 or (201) 389-0920 for international callers. The conference call will be webcast live and include
$63.3 million of Net Revenue Q2 2024 +25.7% net revenue Comparable Growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023 NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended June 30, 2024 ("Q2 2024") and six months ended June 30, 2024 ("H1 2024") on Form 6-K to the U.S. Securities and Exchange Commission, which are also available on the Company's investor relations site at http://ir.waldencast.com/. Michel Brousset, Waldencast Founder and CEO, said: "We
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Argan, Inc. (NYSE:AGX) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results. Argan posted quarterly earnings of 58 cents per share, beating market estimates of 52 cents per share. The company's quarterly sales came in at $157.68 million versus expectations of $134.75 million, according to data from Benzinga Pro. Argan shares climbed 11.1% to $76.78 on Thursday. Here are some other big stocks recording gains in today’s session. Geron Corporation (NASDAQ:GERN) shares climbed 26% to $4.90 as the company reported the FDA approva
DA Davidson analyst Linda Bolton Weiser maintains Waldencast (NASDAQ:WALD) with a Buy and lowers the price target from $15.5 to $6.5.
Telsey Advisory Group analyst Dana Telsey maintains Waldencast (NASDAQ:WALD) with a Outperform and maintains $8 price target.